Učitavanje...

Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1

ABT-737 is a small-molecule antagonist of BCL-2 currently under evaluation in clinical trials in the oral form of ABT-263. We anticipate that acquired resistance to this promising drug will inevitably arise. To study potential mechanisms of resistance to ABT-737, we derived resistant lines from init...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Yecies, Derek, Carlson, Nicole E., Deng, Jing, Letai, Anthony
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2010
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2858493/
https://ncbi.nlm.nih.gov/pubmed/20197552
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-07-233304
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!